PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations (scientific article published on 27 January 2016)

The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study

Q30656720

The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population

Q33991747

A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes

Q34115258

GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer

Q36956156

Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials

Q43868430

PPM1D mutations in circulating white blood cells and the risk for ovarian cancer.

Q51182994

RE: PPM1D mutations in circulating white blood cells and the risk for ovarian cancer

Q57097208

Contribution ofBRCA1andBRCA2mutations to inherited ovarian cancer

Q59688934

Molecular wanderings through the DNA damage response and risk for ovarian cancer

Q86821628

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

ovarian cancer

Q172341

P577

publication date

2016-01-27

P1433

published in

Journal of the National Cancer Institute

Q400279

P1476

title

PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations

P478

volume

108

Reverse relations

cites work (P2860)

Q91211233	Cancer genetics, precision prevention and a call to action
Q34548829	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.
Q89651152	Clonal hematopoiesis in cancer
Q34556382	Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly
Q40063882	De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome
Q92237320	Detectible mosaic truncating PPM1D mutations, age and breast cancer risk
Q37624593	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Q47157222	Mosaic mutations in blood DNA sequence are associated with solid tumor cancers
Q57284432	Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings
Q58547326	PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy
Q89320681	PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells
Q40397279	Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium
Q93046091	Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy
Q30239099	The ageing genome, clonal mosaicism and chronic disease
Q89479770	The role of PPM1D in cancer and advances in studies of its inhibitors
Q38627087	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes
Q30240431	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?
Q38611096	Therapy-related myeloid neoplasms: when genetics and environment collide
Q39613092	Truncating and missense PPM1D mutations in early-onset and/or familial/hereditary prostate cancer patients.
Q99572138	Unique roles of rare variants in the genetics of complex diseases in humans